HUMALOG Drug Profile

Summary for Tradename: HUMALOG

High Confidence Patents:	2
Applicants:	1
BLAs:	4
Drug Prices:	Drug price information for HUMALOG
Recent Clinical Trials:	See clinical trials for HUMALOG

See drug prices for HUMALOG

Recent Clinical Trials for HUMALOG

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Stanford University	PHASE1
Xentria, Inc.	PHASE1
Steno Diabetes Center Copenhagen	NA

See all HUMALOG clinical trials

Pharmacology for HUMALOG

Ingredient-type	Insulin
Established Pharmacologic Class	Insulin Analog

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and company disclosures

These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for HUMALOG Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for HUMALOG Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Eli Lilly And Company	HUMALOG	insulin lispro	Injection	205747		2014-06-16	DrugPatentWatch analysis and company disclosures
Eli Lilly And Company	HUMALOG	insulin lispro	Injection	205747		2013-05-07	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for HUMALOG Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Eli Lilly And Company	HUMALOG	insulin lispro	Injection	020563		2033-06-12	Patent claims search
Eli Lilly And Company	HUMALOG	insulin lispro	Injection	020563		2036-12-20	Patent claims search
Eli Lilly And Company	HUMALOG	insulin lispro	Injection	020563		2035-08-21	Patent claims search
Eli Lilly And Company	HUMALOG	insulin lispro	Injection	020563		2035-07-16	Patent claims search
Eli Lilly And Company	HUMALOG	insulin lispro	Injection	020563		2036-09-08	Patent claims search
Eli Lilly And Company	HUMALOG	insulin lispro	Injection	020563		2036-06-14	Patent claims search
Eli Lilly And Company	HUMALOG	insulin lispro	Injection	020563		2037-02-13	Patent claims search

Market Dynamics and Financial Trajectory for HUMALOG

Last updated: April 8, 2026

What is HUMALOG and its market position?

HUMALOG is a rapid-acting human insulin analog used primarily for glycemic control in diabetes mellitus type 1 and type 2. It has been marketed by Eli Lilly and Company since 1996. HUMALOG, with the active ingredient insulin lispro, competes directly with biosimilars and other fast-acting insulins.

How has HUMALOG's market share evolved?

HUMALOG maintains a significant share of the rapid-acting insulin market, though it faces increasing competition from biosimilars such as Admelog (also by Eli Lilly, based on insulin lispro with approval in 2017) and other brands like NovoLog/NovoRapid (by Novo Nordisk). Estimates suggest HUMALOG accounted for approximately 20-25% of the global fast-acting insulin market in 2022.

What are the primary drivers of market growth?

Several factors influence growth:

• Rising global diabetes prevalence: The International Diabetes Federation reports over 537 million adults with diabetes globally as of 2021, projected to reach 643 million by 2030. Growth in insulin-dependent populations supports volume expansion.
• Healthcare infrastructure improvements: Better diagnosis and access, especially in emerging markets like China, India, and Brazil, boost demand.
• Innovative formulations: Eli Lilly's development of concentrated formulations (e.g., HUMALOG U-200) enhances patient compliance.
• Pricing and reimbursement landscape: Reimbursement policies in key markets influence prescribing patterns and sales volume.

How does patent lifecycle impact HUMALOG?

HUMALOG's original patent expired in the mid-2010s, allowing biosimilar entry. Eli Lilly's patent protection extended until 2023 for certain formulations. The launch of biosimilars diminishes exclusivity-based pricing power, pressuring margins. However, Lilly's branding and incremental product innovations preserve a competitive edge.

What are revenue estimates and projected financial trajectories?

In 2022, HUMALOG generated approximately $1.2 billion globally, representing around 20-25% of Eli Lilly's insulin segment revenue.

Revenue breakdown:

Year	Revenue (USD billion)	Market Share	Comments
2020	1.5	30%	High growth driven by emerging market sales
2021	1.4	23%	Biosimilar competition intensifies
2022	1.2	20-25%	Patent cliffs and biosimilar entries

Projections indicate a decline in HUMALOG revenue through 2025 unless product line extensions or new indications emerge. The segment could stabilize with increased use of concentrated formulations or fixed-dose combinations.

What is the competitive landscape?

Major competitors include:

• Novo Nordisk: NovoRapid/NovoLog, with a leading insulin portfolio.
• Sanofi: Apidra, less dominant but present.
• Biosimilars: Admelog (Lilly), authorized in multiple markets; generic insulin lispro versions in development.

Market entry of biosimilars has led to price reductions, pressuring revenue.

How do regulatory policies influence market dynamics?

In the U.S., the Biosimilar Price Competition and Innovation Act (2010) allows biosimilar approval pathways. The increased availability of biosimilars in the European Union and the U.S. reduces HUMALOG's pricing power.

Emerging markets often lack strong biosimilar regulations, enabling continued sales growth there, especially in countries with growing diabetes prevalence.

What does the future hold for HUMALOG’s financial trajectory?

Potential growth avenues include:

• Launch of concentrated formulations (U-200, U-300) improving convenience.
• Expansion into emerging markets with rising diabetes rates.
• Strategic collaborations or acquisitions to broaden insulin options.

However, biosimilar competition and patent expirations limit pricing flexibility and profit margins.

Key Takeaways

• HUMALOG is a leading rapid-acting insulin with a market share of approximately 20-25% globally.
• Revenue has declined from $1.5 billion in 2020 to $1.2 billion in 2022.
• Biosimilar entry has increased price competition, impacting margins.
• Growth relies on market expansion in emerging economies and product innovation.
• Regulatory policies favor biosimilar proliferation, pressuring traditional brand revenues.

FAQs

1. How does HUMALOG compare with biosimilars?
Biosimilars like Admelog are chemically similar but typically priced lower. They capture market share, leading to revenue pressure for HUMALOG.

2. What are the key risks facing HUMALOG’s revenue?
Patent expirations, biosimilar competition, and pricing pressures in mature markets are primary risks.

3. Which markets are driving growth for HUMALOG?
Emerging markets such as China, India, and Latin America exhibit rising diabetes prevalence and expanding access, offering growth potential.

4. Can product innovations reverse revenue declines?
Yes, concentrated formulations and combination products can improve patient adherence and expand usage, potentially stabilizing revenues.

5. What regulatory changes could impact HUMALOG?
Approval and reimbursement policies favoring biosimilars, and patent litigation outcomes, influence pricing and market share.

References

[1] International Diabetes Federation. (2021). IDF Diabetes Atlas, 9th Edition.
[2] Eli Lilly and Company. (2023). HUMALOG product information.
[3] U.S. Food and Drug Administration. (2017). Approval of Admelog (insulin lispro).
[4] European Medicines Agency. (2019). Regulatory guidelines for biosimilars.
[5] IQVIA. (2022). Global Insulin Market Data.